Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients

Background: Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) of the face and scalp. Methods: We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate the efficacy and tolerability of tirbanibulin in a real-life setting. 250 patients were enrolled. Tirbanibulin, 1% ointment, was applied daily for five consecutive days. The efficacy of treatment was measured with modifications of the Actinic Keratosis Area and Severity Index (AKASI). A satisfactory response was defined by complete (100% reduction in the number of lesions) or partial clearance (75-99%) of treated AKs. Results: Overall, the AKASI score was significantly reduced in the studied population (mean, from 4.1 ± 2.7 to 1.4 ± 1.5; P < 0.001). A satisfactory response was observed in 222 (88.8%) cases. The proportion of satisfactory responses was higher when follow-up was performed after 8 weeks (34/35, 97.1%). The reduction in AKASI was significant in patients with Olsen grade II or III lesions (from 5.3 ± 2.8 to 1.6 ± 1.6; P < 0.001). A satisfactory response was observed in 91/104 (87.5%) cases. AKASI reduction was also significant in patients with trunk or limb AKs (from 7.0 ± 1.3 to 2.0 ± 1.6; P = 0.018) since a satisfactory response was observed in 7/8 (87.5%) cases. Tirbanibulin was well tolerated; all adverse events (AEs) included transient local reactions at the site of treatment. Overall, 231 patients had at least one AE. Only 7 (2.8%) grade 4 AEs were recorded. Conclusion: Our retrospective study confirmed that tirbanibulin 1% ointment is effective and well tolerated in a real-life setting and is also promising for Olsen grade II and grade III AKs and AKs localized on difficult-to-treat areas

Nicotinamide counteracts UVB-induced cytotoxic effects and aquaporins overexpression on A375 melanoma cell line

Background/objectives: Ultraviolet-B (UVB) represents a major extrinsic factor in skin cancer development, causing cellular changes that are not yet fully understood. Aquaporins (AQPs) are a family of transmembrane proteins that favor water transport and are involved in several pathways. Nicotinamide (NAM), a vitamin B3 derivate, is a safe molecule able to reduce UVB-induced damages. This study aims to verify whether AQP expression is affected by UVB exposure at different dosages and times and to evaluate NAM’s effects against UVB-induced damages. Methods: A375 cells were exposed to 40, 100, and 200 mJ/cm2 UVB doses and analyzed 0, 1, 18, and 24 h post-irradiation. Results: We found that the 40 mJ/cm2 UVB dose, 24 h post-irradiation, caused the most detrimental effects an overall overexpression and dimerization of AQPs. However, in the presence of NAM 25 μM, the cell cycle was restored, leading to improved cell viability and proliferation, reduced ROS levels, and reduced DNA damage. Moreover, we found decreased AQPs expression and dimerization. Conclusions: Overall, NAM effectively mitigates UVB-induced cellular damage, including AQPs overexpression, and may serve as a protective agent against UVB-related skin damage